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Preface
The 'invisible hand' is a term originally coined by Adam Smith in the Theory of Moral Sentiments
to describe the forces of self-interest, competition, and supply and demand that regulate the
resources in society. This metaphor continues to be used by economists to describe the self-
regulating nature of a market economy. The same metaphor can be used to describe the RHO-
specific guanine nucleotide dissociation inhibitor (RHOGDI) family, which operates in the
background, as an invisible hand, using similar forces to regulate the RHO GTPase cycle.
Introduction
RHO family GTPases control a wide variety of cellular processes, including cell adhesion,
migration and proliferation (Box 1). At any given time, only a small fraction of all RHO
GTPases present in the cell are in the active state and are associated with membranes. The
inactive pool is maintained in the cytosol by associating with RHO-specific guanine
nucleotide dissociation inhibitors (RHOGDIs).
Despite the wide diversity in the RHO GTPase family, there are only three genes encoding
RHOGDI in mammals (Box 2) 1. RHOGDI1 (also known as RHOGDIα) is the most
abundant and best-characterized member of the family; it is ubiquitously expressed and
interacts with several RHO GTPases, including RHOA, RHOC, RAC1, RAC2 and
CDC42 2, 3. RHOGDI2 (also known as RHOGDIβ, Ly-GDI and D4-GDI) is expressed in
high levels by haematopoietic cells4, 5, but has been also found to be expressed in other
tissues, as well as by cancer cells (see below). RHOGDI2 associates with several RHO
GTPases in vitro, but with significantly lower affinity than RHOGDI16. However, many of
these interactions have not been detected in vivo7. RHOGDI3 (also known as RHOGDIγ) is
the most divergent of the three and contains a unique amino-terminal extension that targets it
to the Golgi complex and other cellular membranes8. RHOGDI3 is usually expressed at low
levels and seems to interact predominantly with RHOB and RHOG8-10. Completing the
catalogue of binding specificities of RHOGDIs to the different RHO GTPases, which is far
from comprehensive, should shed some light on the differences in the functions of the
different isoforms.
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Although originally considered to be passive regulators, recent studies have shown that the
RHOGDI family have a key role in the regulation of RHO GTPases. Like an 'invisible
hand'—a term originally coined by Adam Smith in the Theory of Moral Sentiments to
describe the forces of self-interest, competition and supply and demand that regulate the
resources in society11—RHOGDIs operate in the background, controlling key aspects of the
RHO GTPase cycle. In this Review, we discuss how RHOGDIs regulate RHO GTPases, by
modulating the extent of their expression, their membrane localization and their activation
state. We also describe the mechanisms by which the interaction between RHOGDIs and
RHO GTPases is regulated, and how, in many cases, this regulation can be selective for each
type of RHO GTPase. Changes in the levels of expression of the different RHOGDIs have
marked effects on the overall levels and activities of RHO GTPases and have been
correlated with several types of cancer.
RHOGDI functions
RHOGDIs were initially characterized as simply RHO GTPase inhibitors; however, recent
work indicates that their function is more complex 12.
RHOGDIs as negative regulators of RHO GTPases
The first RHOGDI (RHOGDI1) was originally discovered in the pre-genomics era, when
new proteins were still identified on the basis of their biochemical properties and function.
RHOGDI (or RHOB p20 GDI, as it was named then) was initially purified from rabbit
intestine and later cloned from bovine brain tissue2, 13. It was characterized as a protein
capable of inhibiting some of the basic features of RHO proteins, (and not of RAS, RAP and
RAB), such as the release of GDP and the loading of GTP to RHO-GDP. RHOGDIs do not
prevent loading of GDP or GTP to a nucleotide-free RHO; this means that they inhibit the
release of the nucleotide and not its binding to the RHO GTPase 13. It was therefore clear
that its biochemical activity was different from that of guanine nucleotide exchange factors
(GEFs) and GTPase activating proteins (GAPs). RHOGDIs were also found to inhibit the
GTPase activity of RHO proteins, preventing both intrinsic and GAP-stimulated hydrolysis
of GTP 14. This dual inhibitory function would later be understood from the structure of
RHOGDI complexed with a RHO GTPase. The N-terminal domain of RHOGDI interacts
with the switch I and switch II domains of the RHO protein (see below) and restricts the
spatial flexibility that is required for the transition between different nucleotide-bound forms
of the RHO GTPase, essentially 'locking up' the GTPase. Conceptually, RHOGDI seemed to
function in the RHO switch (Box1) simply as an inhibitory molecule that bound mostly to
inactive RHO GTPases and preventing nucleotide exchange. This view of RHOGDI as an
inhibitory regulator was extended by the observation that RHOGDI can extract RHO
proteins from membranes and hold them in a complex in the cytosol away from their sites of
action at membranes3.
RHOGDIs as chaperones
Given that RHO GTPases are prenylated and act at membranes, it is somewhat surprising
that the largest fraction of each family member is found in the cytosol 12, 15. One of the main
functions of RHOGDIs is to maintain a stable soluble pool of inactive RHO GTPases, which
at any given time may account for most (90–95%) of the RHO proteins in the cell 12, 15. A
generally accepted explanation for this cytosolic pool is that it acts as a reservoir, allowing
inactive RHO GTPases to be rapidly translocated to any membrane in the cell for activation
in response to specific signals. This 'instant deployment' strategy would allow cells to
respond quickly to any stimulus or challenge that requires the activation of a particular RHO
GTPase. It is important to note here that most of the studies have examined the effects on
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the cytosolic pool of the major RHO GTPases — RAC1, RHOA and CDC42 — and
findings may not apply to all family members.
One of the problems associated with maintaining a soluble RHO GTPase pool is the
hydrophobic isoprenoid moiety at the carboxyl terminus of all RHO proteins. Isoprenylation
of RHO proteins is essential for their proper subcellular localization and signalling16.
However, in the absence of membranes, the isoprenoid moiety, which is highly
hydrophobic, impairs the ability of RHO GTPases to fold properly12. Binding to RHOGDI
stabilizes the cytosolic RHO pool and shields the isoprenyl group from exposure to water by
inserting it into a hydrophobic pocket in the C-terminal half of the molecule. Consistent with
this, phosphorylation of RHOA on Ser188 increases its affinity for RHOGDI and protects it
from degradation (see below)17.
This function of RHOGDIs has always been considered to be more of a 'housekeeping' role
and has not been characterized in detail. However, it was recently found that, in the absence
of RHOGDI1, the cytosolic pool of RHO GTPases is unstable and rapidly degraded in a
proteasome-dependent manner (Fig. 1)12. In the absence of the isoprenyl group, RHO
GTPases are much more stable, although their signalling is impaired because they fail to
localize to their sites of action at specific membranes. In this way, RHOGDIs act as
chaperones, not as much in assisting the folding of newly synthesized proteins (although it is
possible that this occurs), but by stabilizing the mature RHO GTPases when they are not
associated with membranes. Even though a chaperone function for RHOGDIs has been long
recognized18, their role in protecting against degradation was generally overlooked.
RHOGDI shuttle RHO GTPases between membranes
Since the discovery that RHOGDIs can extract RHO proteins from membranes, the idea that
RHOGDIs may shuttle RHO GTPases between different membrane compartments has been
prevalent. However, evidence has been presented both for and against this, and the debate
continues. In a series of papers, Wilson-Delfosse and colleagues19-21 designed RHO GTPase
mutants (Arg66Glu in RAC1 and CDC42, Arg68Glu in RHOA) that cannot bind to
RHOGDIs and hypothesized that, if RHOGDI is required to shuttle RHO proteins between
membranes, the mutated proteins should be mislocalized and not functional. By expressing
constitutively active RHO GTPases, they found no significant difference in the signalling
between the forms that were able or unable to bind to RHOGDIs. Similarly, RHOGDI-null
cells responded the same way as their wild-type counterparts when constitutively active
mutants of RAC1 and CDC42 were overexpressed19, 20. This led them to conclude that
RHOGDIs are not required for the translocation of RHO GTPases to their membrane
destinations 19-21. Consistent with this, yeast cells lacking Rdi1 (the RHOGDI orthologue)
and RHOGDI1-knockout mice had mild phenotypes 22-24. The RDI1 deletion yeast strain
was indistinguishable from wild-type cells in terms of growth, cell morphology and mating,
but exhibited defects in pseudohyphal growth and mitosis exit22. Similarly, RHOGDI1-
knockout mice reached adulthood normally, suggesting there are other mechanisms that can
control the cycling of RHO GTPases 23, 24.
By contrast, Cerione's group found that, although a fast-cycling mutant of CDC42
(Phe28Leu) induced cell transformation, this property was lost when a second mutation
(Arg66Ala) that impaired binding to RHOGDI was introduced 25. CDC42 Phe28Leu can
undergo spontaneous GTP–GDP exchange while maintaining full GTPase activity26, and,
unlike GTPase-defective CDC42 mutants (which are toxic to cells), can be stably expressed
and exhibit properties of oncogenic transformation. Unable to associate with RHOGDI, the
CDC42 double mutant, accumulated in membranes in the perinuclear region rather than
reaching the plasma membrane25. Similarly, another group found that the Arg66Glu RAC1
mutant, which cannot bind RHOGDI, failed to translocate to the plasma membrane in
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response to hepatocyte growth factor (HGF) stimulation (which normally activates
RAC1)27. Fractionation of cells has revealed a biphasic distribution of membrane-associated
RHOA, RAC1 and CDC42, with most found in the endoplasmic reticulum (ER) and a
smaller amount of each one in the plasma membrane fraction. Depletion of RHOGDI1,
however, causes a marked reduction in the levels of each GTPases that are associated with
the plasma membrane 12, suggesting that RHOGDIs are involved in the transport of RHO
GTPases to the plasma membrane.
How can this contrasting evidence be reconciled? One possibility is that there are other
RHOGDI-like molecules compensating for the loss of RHOGDIs. For example, recent work
shows that caveolin 1 binds to CDC42 and sequesters it in its GDP-bound form at secretory
granules 28. CDC42 is required for insulin granule exocytosis, during which it is proposed to
function in targeting the secretory granules to specific sites at the plasma membrane29. Upon
stimulation by glucose, CDC42 is dissociated from caveolin 1 and subsequently activated,
allowing the secretory granules to fuse with the plasma membrane. Mechanistically,
caveolin 1 assumes some of the properties of RHOGDIs by sequestering inactive CDC42
and restricting fusion of secretory granules. It will be interesting to discover whether other
membrane-bound RHOGDI-like molecules contribute to the spatial and temporal regulation
of RHO GTPases.
However, there is evidence against this theory: in the absence of RhoGDIs, essentially no
RHO GTPases are detected in the cytosol 12. An alternative explanation, which we favour,
comes from studies in yeast, in which there is evidence supporting the coexistence of two
mechanistically distinct recycling systems for CDC42, a fast-cycling mechanism involving
Rdi1 and a slower one involving vesicle trafficking (Figure 1)30. At the early stages of bud
formation, CDC42 is targeted to a small region in the plasma membrane that later becomes
the bud site, where it functions to orchestrate the polarization of the actin cytoskeleton
(which is required to direct secretory traffic to the budding site) 31. Deletion of the Rdi1
significantly decreases the rate of exchange of CDC42 between the plasma membrane and
the cytosol30 but has no obvious growth phenotype, owing to the presence of the endocytic
recycling pathway. However, when both pathways are inhibited, the polarization of CDC42
at the bud site is rapidly lost.
We favour the idea of vesicle trafficking accounting for the small amount of RHO proteins
that can reach the plasma membrane in mammalian cells lacking RHOGDI1. The existence
of two pathways by which RHO GTPases reach their membrane destinations provides an
explanation for how constitutively active RHO proteins that cannot interact with RHOGDI
can still exert their effects19, 20. Without binding to RHOGDI, a fraction of RHO GTPases
continues to be transported to the plasma membrane through vesicle trafficking; this occurs
at a reduced rate, but one sufficient to account for their phenotype. We suspect that the mild
phenotype of the RHOGDI1-knockout mice also results from sufficient transport of RHO
proteins occurring through vesicle trafficking.
Structural analysis of RHOGDI–RHO GTPase
RHOGDI1 has been crystallized in complex with CDC42, RHOA and RAC132-34 (Figure
2), whereas the structure of RHOGDI2 has been solved in complex with RAC235. These
structures provide snapshots of the key residues involved in regulating the interactions and
have provided the information necessary for mutagenesis studies that characterized the
importance of these residues.
The structure of RHOGDIs comprises two main domains: a C-terminal domain (amino
acids74–204) — which includes the geranylgeranyl-binding pocket and is required to extract
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RHO GTPases from the membrane — and a 'regulatory arm' at the N-terminus (amino acids
5–55) — which inhibits exchange and hydrolysis through interactions with the switch I and
switch II domains in the RHO GTPases. The isoprenyl-binding domain adopts an
immunoglobulin-like fold, and the surface of the geranylgeranyl-binding pocket is lined
with hydrophobic residues 32, 34. Insertion of the isoprenyl moiety perturbs the structure of
the RHOGDI, displacing the β-strands βH and βI by 2.0Å, as well as several individual
amino acids, to overcome steric hindrances imposed by the isoprenyl moiety. The N-
terminal region of RHOGDIs, which is flexible and disordered when in solution, folds into
two antiparallel helices upon formation of the complex and interacts with the switch I and
switch II domains of the RHO GTPases (Figure 2)32, 34, 35.
It is interesting to note that RHOGDIs can accommodate both GTP- and GDP-bound forms
of RHO GTPases 18, 36. Structural studies have shown that the main interaction sites
between RHOGDIs and RHO GTPases are virtually unaffected by the nucleotide state 37.
Numerous key residues have been identified in the interface between RHOGDIs and RHO
GTPases, including Thr35, Tyr64, Arg66, His103 and His104 (amino acid numbering refers
to RAC1 and CDC42), which form hydrogen bonds with RHOGDIs. Thr35, located in the
switch I domain, is particularly important for the interaction, as it is conserved in all
GTPases and is required for the coordination of Mg2+ (which is essential for stabilizing the
nucleotide). The regulatory arm in RHOGDIs interacts with Thr35 in CDC42 by forming a
hydrogen bond with Asp45. Arg66, which is located in the switch II region and forms
hydrogen bonds with Asp185, Pro30 and Ala31, is another key residue in the RHOGDI -
RHO GTPase interaction; substitution of the RHO GTPase Arg66 for Glu (or of Arg68 in
RHOA) abolishes the interaction with RHOGDIs 19-21. Interestingly, the RHOGDI- RHO
GTPase interaction can be rescued with a charge-reversing substitution in Asp185 in
RHOGDI (Asp185Arg) 20.
Based on structural and experimental data, a two-step mechanism has been proposed to
explain how RHOGDIs extract RHO GTPases from the membrane 36. First, the N terminus
of the RHOGDIs associates with the switch I and switch II domains of the RHOGTPase.
This initial binding step is followed by a slower isomerization event that results in the
isoprenyl group swapping from the membrane to the hydrophobic pocket 32, 38. The acidic
patch in the RHOGDI geranylgeranyl-binding pocket may contribute to the extraction by
competing with acidic phospholipids for binding to the polybasic tail of the RHO GTPase. It
was recently shown that, in the presence of membranes, RHOGDIs have a much higher
affinity for CDC42-GDP (inactive) than for CDC42-GTP (active) 38. By selectively
extracting the GDP-bound (inactive) forms of RHO GTPases from membranes, RHOGDI
could contribute to the concentration of active GTPases at the membrane.
Regulation of RHOGDI–RHO GTPase interactions
Selective activation of a single RHO GTPase by a signalling pathway requires the release of
that RHO family protein from the RHOGDI. But here there is a conundrum because each of
the three mammalian RHOGDIs interacts with multiple RHO GTPases. How can a single
RHO GTPase be released from the RHOGDI selectively? In addition, our recent findings
argue that displacement of a RHO GTPase from RHOGDI has to be coupled to its
association with cell membranes (or some other entity) to prevent its degradation 12. Based
on similar G proteins, such as members of the RAB family, the existence of a GDI
dissociation factor (GDF) has been postulated. By definition, a GDF interacts with
RHOGDIs and promotes the dissociation of the RHOGDI-RHO GTPase complex, rendering
the RHO GTPase available for activation by GEFs. However, in contrast to the RAB system,
a conserved GDF for RHO proteins has not been found. Evidence for a range of mechanisms
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has been provided, which are discussed below. Some of them regulate the specific
displacement of a single RHO GTPase from RHOGDI, whereas others displace all the RHO
GTPases equally.
Release by lipids
Early work revealed that RHOGDI–RHO GTPase complexes could be disrupted by acidic
lipids 39, and subsequent work showed that phosphoinositide lipids could open up
RHOGDIs, thereby facilitating GEF-mediated exchange on bound RHOA 40. A role for
lipids in the release of RHO GTPases from RHOGDI was shown during integrin-mediated
adhesion 41, 42. In suspended cells RAC1-GTP was found to be retained in the cytosol
complexed with RHOGDI; however, integrin-mediated adhesion could mediate the
dissociation of RAC1 from the RHOGDI. A lipid raft seemed to be responsible for the
recruitment of RAC1 to sites of integrin engagement, and liposomes that were similar in
lipid composition to lipid rafts were found to dissociate Rac1-GTP from RHOGDI 41.
Another study using liposomes found that prenylated RAC1 bound to RHOGDI was
inaccessible for nucleotide exchange mediated by the DBL homology domain (DH domain)
and pleckstrin homology domain (PH domain) of the GEF T lymphoma invasion and
metastasis-inducing 1 (TIAM1). However, nucleotide exchange could be observed when
liposomes were added, and this corresponded specifically to a fraction of RAC1 dissociating
from RHOGDI and binding to the liposomes 43. On the basis of these results, the authors
proposed a two-step model for the activation of RHO GTPases: their release from
RHOGDIs is promoted by lipids (FIG. 3a), which then leads to their activation by GEFs.
To examine this model further, another group measured exchange using liposomes of
defined composition with RHOGDI bound to prenylated RAC1 and active DH and PH
domains of the GEFs TIAM1 or TRIO. They found that liposomes containing
phosphoinositides co-operated with active GEFs to promote the release of RAC1 from the
RHOGDI 44. Like the previous group, these investigators favoured a two-step model,
although the nature of their experimental conditions could not rule out a one-step model in
which the GEF activity promoted dissociation of the RHOGDI–RAC1 complex.
Interestingly, in these experiments it was observed that if GTP was replaced with GDP,
RAC1 did not dissociate from the RHOGDI and did not become associated with the
liposomes44. This is consistent with the finding that, in the presence of membranes,
RHOGDI has a lower affinity for GTP-bound RHO GTPases than GDP-bound ones 38.
Nevertheless, exchange did occur in the RHOGDI complex, indicating somewhat
unexpectedly that the GEFs used in this experiment (TIAM and TRIO) could act on RAC1
complexed with RHOGDI. This observation suggests a one-step mechanism of RHO
GTPase activation, but one in which the bound nucleotide (GTP versus GDP) is crucial for
RHO GTPase release.
Release by GEFs
RHOGEFs have always been considered natural candidates for the role of GDFs in the RHO
GTPase system. They act directly downstream of the dissociation event, and because they
discriminate between individual RHO proteins and are targets of the signalling pathways
that activate RHO GTPases, they could provide specificity to the reaction. However,
according to structural analysis, both RHOGEFs and RHOGDIs interact with the switch I
and switch II domains of RHO GTPases, which suggests that the two interactions may be
mutually exclusive32, 45.
Although findings indicate that GEFs can function as GDFs44, in particular in the RAB
GTPase subfamily 46, 47, there is little evidence suggesting that GEFs catalyze displacement
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directly. Furthermore, even though a role for GEFs has been proposed in the two-step
mechanism of RHO GTPase activation (see above), the two steps are mechanistically
distinct 43; more work is needed to establish whether RHOGEFs have direct roles as GDFs
or whether their actions are confined to the second step, activating the RHO protein that has
been released from RHOGDI into the membrane.
Release by specific protein interactions
Another possibility is that specificity in the dissociation of the RHOGDI–RHO GTPase
complex is afforded by distinct protein–protein interactions. For example, ezrin, radixin, and
moesin (ERM) proteins, p75 neurotrophin receptor (p75NTR; also known as NGFR) and the
Tyr kinase ETK have all been reported to promote the displacement of RHO GTPases from
RHOGDI 48-51(FIG.3b). The N terminus of ERM proteins associates with RHOGDIs and
can compete for binding to all RHO GTPases tested, thereby inhibiting RHOGDI function
and promoting the activation of RHO proteins 50, 52. However, in vivo data suggest that
ERM proteins may regulate the preferential release of RHOA50, 53. Interestingly, radixin
also interacts with the GEF DBL, suggesting it may couple release of the GTPase from
RHOGDI with activation52.
p75 NTR is a neurotrophin receptor that functions in the regulation of axonal elongation by
neurotrophins and by several myelin-derived proteins. Neurotrophins stimulate neurite
outgrowth by inhibiting RHOA activity, whereas myelin-derived proteins activate RHOA
and inhibit axonal elongation. The ability of p75NTR to modulate RHOA activity depends on
its ability to interact with RHOGDI to promote RHOA release and subsequent activation 51.
Myelin-derived proteins, such as neurite outgrowth inhibitor (NOGO) or myelin-associated
glycoprotein (MAG), enhance the association of p75 NTR with RHOGDIs, which suggests
that they activate RHOA by inducing its release from the RHOGDI (Figure 3)51.
ETK is a non-receptor Tyr kinase that belongs to the Bruton Tyr kinase (BTK) family and
has been shown to have a role in the regulation of various cellular processes, including
cytoskeletal reorganization and cell motility 54. ETK promotes the specific displacement of
RHOA (but not RAC1 and CDC42) from RHOGDI1 in a kinase-independent manner 48.
ETK interacts with RHOA through an N-terminal PH domain and competes for its binding
to RHOGDIs, promoting its release and subsequent activation 48.
Release by phosphorylation
In recent years, phosphorylation has emerged as one of the key post-translational
modifications that can selectively alter the affinities of the different RHO GTPases for
RHOGDIs for one another. In general terms, phosphorylation of RHOGDIs decreases their
affinity for RHO GTPases, promoting RHO GTPase release and making them available for
activation. By contrast, phosphorylation of RHO GTPases increases their affinity for
RHOGDIs, promoting their sequestration and inactivation in the cytosol (Table 1).
This suggests that, at least to a certain extent, some kinases can function as bona fide GDFs.
For example, phosphorylation of RHOGDI1 on Ser101 and Ser174 by p-21-activated kinase
(PAK1) reduces its affinity for RAC1 but not RHOA, promoting the release of RAC1 and its
subsequent activation 55. Similarly, phosphorylation of RHOGDI1 on Ser34 by protein
kinase Cα (PKCα) selectively releases RHOA (but not RAC1or CDC42) and promotes its
activation 56. Ser101 and Ser174 are located in the hydrophobic binding cleft of RHOGDI
on its solvent-exposed surface, suggesting their phosphorylation could perturb binding of the
isoprenyl moiety of the RHO GTPase32 (FIG. 2). However, as the phosphorylation-mediated
release is specific for RAC1, it is possible that interactions with the polybasic region, the
most divergent sequence between RHO GTPases, may also be affected by the negative
Garcia-Mata et al. Page 7













charge afforded by the phosphorylation and contribute to release. Ser34 is located in the N-
terminal regulatory arm of RHOGDIs, which interacts primarily with the switch II domain
of RHO GTPases 32. This region folds into a helix-loop-helix motif that is maintained
mainly by hydrophobic interactions, so it is possible that the negative charge from the
phosphate group interferes with the RHO GTPase interaction (FIG. 2). In addition, Ser34 is
surrounded by many key residues in the N terminus of the RHOGDI, which interact with
Arg66 (in CDC42 and RAC1), a residue in RHO GTPases that is essential for the interaction
with RHOGDIs (and correlates with Arg68 in RHOA, RHOB and RHOC) 19-21. It is
therefore possible that phosphorylation of Ser34 disrupts or interferes with the interactions
surrounding Arg66, triggering displacement. However, Arg66 is conserved in most RHO
GTPases, so it is not clear how Ser34 affects specifically RHOA but not RAC1 and CDC42
release.
It is tempting to speculate that a RHOGDI phosphorylation code (similar to the histone
modification code) controls which RHO GTPase is to be released from the complex in
response to a stimulus. This attractive idea, which has been previously postulated 1, would
solve the requirement for a GDF in an elegant way. However, this hypothesis is hard to
justify based on the sequence and structural data. The residues that are phosphorylated in
RHOGDIs are either concentrated around the geranylgeranyl-binding pocket or in the
regulatory arm region that interacts primarily with the switch II region in the RHO GTPase
(FIG. 2 and Table 1), so interfering with binding to the prenylated region of RHO GTPases
should affect all RHO proteins the same way. The same can be argued for the switch II
region, which is identical in the major RHO GTPases (RHOA, RAC1 and CDC42).
An alternative hypothesis is that selective release of a particular RHO GTPase from the
RHOGDI is achieved by the recruitment of the complex to a specific cellular location, where
the RHOGDI is phosphorylated. This could be mediated by scaffolding proteins that, in
response to a signal, can recruit a particular RHOGDI– RHO GTPase complex to a site of
stimulation. A specific kinase would then phosphorylate the RHOGDI, triggering the release
of the RHO GTPase and allowing its subsequent activation by a RHOGEF. Consistent with
this, a recent report showed that, upon platelet-derived growth factor treatment,
diacylglycerol kinase-ζ (DGKζ) forms a complex with RAC1 and RHOGDI and promotes
the release of RAC1. DGKζ stimulates the production of phosphatidic acid, which induces
PAK activity. PAK subsequently phosphorylates RHOGDI, releasing RAC1 for activation57
(FIG. 3c). In DGKζ-deficient fibroblasts PAK1 phosphorylation and RHOGDI–RAC1
dissociation were attenuated and PAK failed to target properly to focal adhesions.
Similarly, following stimulation by HGF, DGKα was found to promote the formation of
phosphatidic acid, which in this case recruits atypical PKCζ (aPKCζ)– aPKCι, in complex
with RHOGDI and RAC1. The activation of aPKCζ– aPKCι mediates the release of RAC1
from the RHOGDI, allowing its activation 27.
Another example involves the transmembrane receptor syndecan4, a heparan sulfate
proteoglycan. Syndecan4 and its adaptor, synectin (which binds to the intracellular tail of
syndecan 4), form a complex with RHOGDI58, an interaction that increases RHOGDI's
affinity for RHOG. Binding of syndecan4 to its ligand, fibroblast growth factor 2 (FGF2),
promotes the activation of PKCα, which in turn phosphorylates RHOGDI. This mediates the
release of RHOG (but not of RAC1), leading to its activation and further downstream
effects59, 60.
RHOGTPase crosstalk through RHOGDIs
Most RHO GTPases bind to at least one of the three RHOGDIs that are expressed in
mammals 1. In addition, it has been previously shown that the total amount of the most
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abundant RHOGDI is roughly equivalent to the sum of the levels of the three major
RHOGTPases: RAC1, CDC42 and RHOA 61. We have recently shown that RHO proteins
can only exist in complex with RHOGDI or associated with cellular membranes 12. These
results imply that the total levels of the major RHO proteins are determined by the amount
of RHOGDIs in the cell. The limited amount of RHOGDIs generates competitive pressure
between the different GTPases to bind to RHOGDI to avoid degradation (FIG. 1). At steady
state, the RHO GTPases must reach an equilibrium between their ability to bind RHOGDI,
the competition from the other RHO GTPases and their turnover by degradation. This
previously unnoticed crosstalk between RHO GTPases through RHOGDI predicts that any
change in the level of a particular RHO GTPase, or in the affinity of a particular RHO
GTPase for RHOGDI, whether physiologically or experimentally induced, should interfere
with this equilibrium.
We have recently shown that the exogenous overexpression of a single RHO GTPase
competes with endogenous RHO proteins and displaces them from RHOGDI in a dose-
dependent manner, triggering their subsequent degradation 12. In addition, the remaining
membrane-bound RHO proteins are eventually extracted by RHOGDIs, displaced by the
overexpressed protein and degraded. The result is the virtual silencing of both the protein
levels and activity of all endogenous RHO proteins associated with RHOGDIs.
In spite of this result, there is evidence that in some situations the released RHO proteins
may become activated. For example, a recent study observed that increased PKG-mediated
phosphorylation of Ser188 in RHOA in smooth muscle cells increased the binding of RHOA
to RHOGDI and displaced RAC162. However, the released RAC1 became activated, leading
to cell migration. A similar situation was observed in PtK1 epithelial cells, in which PKA
activity was observed to be synchronized with protrusion at the leading edge63. PKA-
mediated phosphorylation of RHOA on Ser188 increased its affinity for RHOGDI and
reduced its activity. It will be interesting to learn whether a similar displacement and
activation of RAC1 is involved in this situation too.
This could have a significant role when the levels of a particular RHO GTPase or RHOGDI
are affected, as occurs in many cancer types (see below), by indirectly affecting the
homeostasis of the RHO GTPase system as a whole, magnifying the effects of altered
expression levels.
Biological roles of RHOGDIs
The only known functions of RHOGDIs are in the context of their interactions with and
regulation of RHO GTPases (for reviews on RHO GTPase functions, see Refs 64, 65).
Briefly, some of the best-characterized effects of RHO GTPases are on the cytoskeleton. For
example, RHOA, RAC1 and CDC42 can all stimulate actin polymerization by interacting
with different effectors. The resulting phenotypes are typically, although not always,
distinct: RAC1 promotes cell spreading, inducing the formation of lamellae at the cell
periphery; CDC42 induces the formation of filopodia; and RHOA induces the formation of
filamentous actin bundles, such as stress fibres, although RHOA-induced lamellae have also
been described in some cell types66. These three ubiquitously expressed RHO family
members exert other effects on the cytoskeleton and coordinately regulate many types of cell
migration. RHO GTPases also play important parts in cell adhesion (both to other cells and
to the matrix), cell polarity, vesicle trafficking, cell cycle progression, gene expression and
differentiation. Indeed, there seem few cellular activities in which RHO proteins do not have
some regulatory role64, 65.
When RHOGDI1 has been investigated by knockdown of protein expression or gene
knockout, the overall levels of all RHO GTPases with which it interacts decrease. There was
Garcia-Mata et al. Page 9













a loss of detectable cytosolic RHO proteins, but the remaining membrane-bound fraction of
each RHO protein is highly activated 12. A similar situation was seen in mammalian cells,
when RHOGDI1 was knocked down, and in yeast when the single RHOGDI was
deleted12, 22, 24. Given these results, a prominent phenotype might be expected; however,
surprisingly, there is only a mild phenotype in yeast and mice22, 24. In mice, the loss of
RHOGDI1 does not affect embryonic development, but the adult mice develop progressive
renal defects, that ultimately lead to death and are attributed to increased RAC1 activity23.
In addition, the male mice are infertile, with impaired spermatogenesis, and there are
problems with implantation of RHOGDI1-null embryos in female mice 24. One possible
explanation for the mild phenotype is that RHOGDI2 compensated for the loss of
RHOGDI1. However, the double knockout of RHOGDI1 and RHOGDI2 produces a
phenotype that is only slightly more severe than the single RHOGDI1 knockout, with
additional immunological defects superimposed on those induced by the loss of
RHOGDI1 67.
Although mice lacking RHOGDIs are viable and develop normally, some effects have been
observed when the behaviour of individual cells has been examined. For example,
knockdown of RHOGDI1 in bladder cancer cells increased their migration, but knockdown
of RHOGDI2 had no effect68. By contrast, silencing RHOGDI1 in a rapidly migrating
melanoma cell line inhibited cell migration 12. At first sight, these contradictory results seem
difficult to reconcile. One potential explanation relates to the two modes of cycling RHO
proteins to the plasma membrane (see above). In the absence of RHOGDIs, the slow
delivery of RHO proteins to the plasma membrane by vesicle trafficking may be sufficient
to satisfy the requirements of slowly migrating cells but inadequate for those migrating
rapidly. The fact that slow cells actually increase their speed of migration is consistent with
the remaining fraction of RHO proteins (particularly RAC1) being highly activated when
RHOGDIs are depleted. So, although the amount reaching the plasma membrane is greatly
decreased, those that do get to this site are activated and stay at the membrane for longer,
thus stimulating migration. By contrast, fast-migrating cells may need to recycle RAC1 or
other RHO proteins to newly formed protrusions at a speed that exceeds that of vesicle
trafficking.
Other phenotypic changes have also been observed in cells depleted of RHOGDI1. For
example, mesangial cells from the knockout mice revealed decreased rates of cell
spreading 69. When vascular permeability was studied in RHOGDI1-knockout mice, an
increase in the basal permeability of the pulmonary vascular endothelium was observed70.
This correlated with increased activity of RHOA in these cells and opening of the
interendothelial junctions.
RHOGDIs and cancer
Changes in RHOGDI1 and RHOGDI2 expression levels have been associated with many
cancers71. However, the changes vary depending on the tumour type. For instance,
RHOGDI1 expression is upregulated in colorectal and ovarian cancer, and in this case high
expression levels correlates with increased invasion and resistance to chemotherapy72-74. By
contrast, RHOGDI1 expression is reduced in brain cancers and correlates with reduced
expression of RHOA and RHOB but not RAC1. The expression levels of the three proteins
are inversely correlated with the degree of malignancy75. In breast cancers, conflicting
results have been reported, with RHOGDI1 expression being increased or decreased in
different studies76, 77. Finally, RHOGDI1 is downregulated in hepatocellular carcinoma, and
its expression was found to be controlled in part by a recently characterized microRNA,
miR-151, which is localized in an intron of the gene encoding focal adhesion kinase (FAK)
and is expressed with it78. During hepatocellular tumour progression, FAK expression
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increases together with miR-151, promoting the downregulation of RHOGDI1 and
facilitating tumour invasion and metastasis78.
The expression levels of RHOGDI2 are also severely altered in a range of cancers79, 80.
RHOGDI2 expression is increased in pancreatic cancers and this correlates with increased
invasiveness 80, 81. The opposite occurs in bladder cancers, in which RHOGDI2 is
downregulated in invasive tumour cells 68, 82, and this decrease correlates with decreased
patient survival 83. Similarly, RHOGDI2 is lost in Hodgkin's lymphoma cell lines, although
here there is no clear correlation with growth or survival 84. In breast tumours the pattern of
expression of RHOGDI2 is complex. There is evidence that RHOGDI2 expression is
biphasic, increasing at the early stages of progression but decreasing sharply during
metastasis85. RHOGDI has also been linked to oestrogen receptor expression and was
identified as part of a predictive gene signature for poor prognosis for tumours that express
oestrogen receptor 86.
The effects of the RHOGDIs on cancers are clearly complex and do not fit a simple
explanatory model. It has to be remembered that the consequences of changes in their
expression are manifested through their actions on multiple RHO GTPases, and that the
levels and activities of these vary significantly in different cell types and different cancers.
Even a single RHO family member can have opposite effects in different tumour types. This
is well illustrated by work on the RAC-specific GEF TIAM1: although it was originally
discovered in a search for genes that promoted T cell invasion and metastasis 87, in epithelial
cells it has the opposite effect, delaying migration but enhancing stable cell–cell junctions88.
In both cases, the effects were due to the TIAM1-mediated activation of RAC1, which,
actually, has different effects in the two cell types. As the interaction of RHOGDI with RHO
GTPases is also governed by phosphorylation on multiple sites, the activities of specific
kinases will likely affect how RHOGDI affects the phenotype of particular cancer cells.
Conclusion
In this Review we have discussed some of the emerging ideas about RHOGDIs, how they
act as chaperones for RHO GTPases, regulating RHO protein stability, and how RHOGDIs
shuttle the GTPases to membranes for activation and interaction with their downstream
targets.
Understanding the factors that control the release of RHO proteins from RHOGDIs is one of
the unresolved but exciting areas in the field. We anticipate that answers to the questions in
this area will come from continued biochemical analysis of this process, using reconstituted
in vitro model systems, as well as from imaging techniques that allow the visualization of
RHOGDI complexes in living cells.
Another topic of considerable interest relates to the crosstalk between RHO GTPases that
occurs through their competitive binding to RHOGDIs. The recent work showing that
phosphorylation of RHOA by PKA increases its binding affinity to RHOGDI1 and results in
displacement and activation of RAC162, illustrates a level of interaction between RHO
proteins that had not been anticipated. The discovery of other examples of crosstalk
mediated by RHOGDIs will strengthen the idea that they contribute actively to RHO protein
dynamics and signalling and are not simply passive inhibitors of the RHO GTPase cycle.
Finally, little is known about how the expression of RHOGDI1 or RHOGDI2 is regulated.
The fact that the level of RHOGDI1 seems to be related to the sum of the expression levels
of the major RHO proteins suggests that there are feedback mechanisms coordinating the
expression of both the RHO GTPases and RHOGDIs. The discovery that miR-151 regulates
RHOGDI1 expression opens a new window on this problem78. We suspect that other factors
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influencing the expression of the RHOGDIs remain to be discovered and that many of these
may be altered in cancer cells. RHOGDIs have been suggested as potential targets for cancer
therapy71, but if this direction is pursued it will be crucial to learn more about the factors
regulating RHOGDI expression particularly in tumour cells.
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Glossary
Prenylated Modified by the attachment of an isoprenoid to a C terminal
cysteine residue.
Isoprenoid Compounds that are derived from isoprene (2-methyl-1,3-
butadiene) linked together in head-to-tail or tail-to-tail
conformations and that comprise farnesyl and geranylgeranyl
molecules that are used in the covalent modification of proteins
on cysteine residues.
Isoprenylation A post-translational modification of proteins by the attachment of
an isoprenoid to a C-terminal Cys. The isoprenoids used, farnesyl
diphosphate or geranylgeranyl diphosphate, are derived from the
same biochemical pathway that produces cholesterol.
geranyl-geranyl A 20-carbon isoprenoid precursor to geranyl-geranylated
proteins. The source of the geranyl-geranyl group is geranyl-
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geranyl pyrophosphate, an intermediate in the HMG-CoA
reductase pathway used by organisms in the biosynthesis of
terpenes and terpenoids.
switch I and II Two regions in RHOGTPases that undergo a conformational
change in the active GTP-bound form and provide a platform for
the selective interaction with downstream effectors.
immunoglobulin-like
fold
A type of protein domain that consists of a 2-layer sandwich of
between 7 and 9 antiparallel β-strands arranged in two β-sheets.
steric hindrance occurs when the size of groups within a molecule prevents
chemical reactions that are observed in related smaller molecules.
Isomerization The process by which one molecule is transformed into another




A domain of about 200 amino acids that has been shown to




A protein domain of approximately 120 amino acids that occurs
in a wide range of proteins involved in intracellular signaling. PH
domains frequently bind to cell membranes by interacting with
acidic phospholipids, such as phosphoinositides.
Biphasic Having two distinct phases.
Lipid raft Membrane microdomains that are enriched in cholesterol,
sphingolipids and lipid-modified proteins such as GPI-linked
proteins and palmitoylated proteins. These microdomains often
function as platforms for signalling events.
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RHO proteins are guanine nucleotide-binding proteins (G proteins also known as
GNBPs) that belong to the larger group of GTPases, which include heterotrimeric G
proteins, elongation factors, tubulins, septins and large GTPases such as dynamin.
Biochemically, GTPases are hydrolase enzymes that bind and hydrolyze GTP. In a
similar way to ATP, GTP can act as an energy carrier, but it also has an active role in
signal transduction, particularly in the regulation of G protein activity. G proteins,
including RHO GTPases, are molecular switches that cycle between an inactive GDP-
bound and an active GTP-bound conformation (see the figure). The transition between
the two conformational states occurs through two distinct mechanisms: activation by
GTP loading and inactivation by GTP hydrolysis. GTP loading is a two-step process that
requires the release of the GDP-bound nucleotide and its replacement by a GTP
molecule. Nucleotide release is a spontaneous but slow process that has to be catalyzed
by RHO guanine-nucleotide exchange factors (RHO GEFs), which associate with RHO
GTPases and trigger the release of the nucleotide. The resulting nucleotide-free binary
complex has no particular nucleotide specificity. However, the cellular concentration of
GTP is markedly higher than that of GDP, which favours GTP loading, resulting in the
activation of RHO GTPase. Conversely, to turn off the switch, GTP has to be hydrolyzed.
This is facilitated by RHO GTPase-activating proteins (RHOGAPs), which stimulate the
intrinsically slow hydrolytic activity of RHO proteins. It is worth noting that, although
GEFs and GAPs are the canonical regulators of this cycle, several alternative
mechanisms, such as post-translational modifications, may fine-tune the RHO switch. In
addition, inactive RHO GTPases are extracted by RHO-specific guanine nucleotide
dissociation inhibitors (RHOGDIs) from cell membranes to prevent their inappropriate
activation and to protect them from misfolding and degradation.
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RHOGDI evolution and orthologues
Guanine nucleotide dissociation inhibitors (GDIs) can be categorized according to their
guanine nucleotide-binding protein (G protein) specificity, but not all G proteins have
GDIs (for example Ras does not, but the RHO and Rab families do). The different GDI
families share some common functional and structural features, but they usually have
unrelated amino acid sequences, suggesting that the families emerged independently
during evolution. The RHOGDI family (see the figure) is defined by a conserved
RHOGDI backbone. In humans, there are three RHOGDI proteins: RHOGDI1 (also
known as RHOGDIα and encoded by ARHGDIA), which is expressed ubiquitously;
RHOGDI2 (also known as RHOGDIβ, Ly-GDI, D4-GDI and encoded by ARHGDIB),
which is expressed by haematopoietic cells among others and is commonly upregulated
in certain tumours; and RHOGDI3 (also known as RHOGDIγ and encoded by
ARHGDIG), which is expressed mostly in the brain. Because RHOGDIs are
evolutionarily conserved proteins, they have several orthologues in other eukaryotes (see
the figure). There is a single RHOGDI in many unicellular and organisms such as
Saccharomyces cerevisiae (Rdi1), and also in protostomes such as Caenorhabditis
elegans (RHI-1) and Drosophila melanogaster (RHOGDI). Other metazoans have two or
three RHOGDIs: for example, Danio rerio has two and Xenopus laevis has three.
Tetrapods, including avians and mammals, generally have three RHOGDIs. Interestingly,
plants such as Arabidopsis thaliana have their own particular set of Rho proteins (ROPs)
and their own specific RHOGDI proteins, which highlights both their differences with
the animal kingdom and the universal necessity to have RHOGDIs despite these
differences. From the study of RHOGDIs in different organisms, it emerges that
RHOGDIs have fundamentally conserved functions in eukaryotes: the regulation of RHO
protein cycling between lipid membranes and the cytosol, the stabilization of RHO
proteins and the inhibition of nucleotide release. The figure was generated by aligning the
sequences of the RHOGDIs using ClustalW and by compiling node distances using the
neighbour-joining method.
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Figure 1. The RHOGDI cycle
(a) Newly synthesized RHO family GTPases are geranylgeranylated and then post-
translationally modified by the protease Ras-converting enzyme 1 (RCE1) and by
isoprenylcysteine carboxyl methyltransferase (ICMT) at the cytoplasmic face of the
endoplasmic reticulum (ER). (b) After geranylgeranylation, RHO proteins associate with
RHO specific guanine nucleotide dissociation inhibitors (RHOGDIs), which sequester them
in the cytosol and protect them from degradation. (c) Free prenylated cytosolic RHO
GTPases are unstable and are rapidly degraded by the proteasome. (d) Several RHO
GTPases can associate with RHOGDI and compete for its binding. Overexpression of a
GTPase can displace the endogenous RHO proteins from RHOGDI targeting them for
degradation. (e) The rate of cycling of the RHOGDI -RHO GTPase complex between the
cytosol and the membrane can be regulated by post-translational modifications on both the
RHO GTPases and the RHOGDI, which modulate the affinity of the interaction. A slower
pathway for recycling RHO proteins through vesicle trafficking has also been postulated. (f)
Once at the membrane, the RHO GTPases can be activated by guanine nucleotide exchange
factors (GEFs) and bind to downstream effectors. Following inactivation by GTPase-
activating proteins (GAPs), RHO GTPases are extracted from the membrane by RHOGDI.
(g) Active RHOA can also be targeted for degradation by the ubiquitin ligase SMAD
ubiquitylation regulatory factor 1 (Smurf1). GGTase, geranylgeranyl transferase.
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Figure 2. Structure of the RHOGDI–RHO GTPase complex
(A) Space filling model showing CDC42 in complex with RHO-specific guanine nucleotide
dissociation inhibitor 1 (RHOGDI1)32. The domains that participate in the interaction are
highlighted and labelled on the struucture. (B) Cartoon representation of the crystal structure
of prenylated CDC42 in complex with RHOGDI 32. The phosphorylated residues are shown
in magenta, CDC42 is shown in green, and RHOGDI1 is shown in gold. These structures are
reproduced from the NCBI Molecular Modeling Database(ID: 1275). C, carboxyl terminus;
GG, geranylgeranyl; N, amino terminus; PBR, Poly Basic Region.
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Figure 3. Mechanisms of regulation of the RHOGDI-RHOGTPase interaction
a | Release by lipids: The presence of acidic phospholipids can promote the release of
RHOGTPases from RHO-specific guanine nucleotide dissociation inhibitors (RHOGDIs).
Phospholipids mediate a partial opening of the complex that exposes the GTPases to RHO-
specific guanine nucleotide exchange factors (RHOGEFs) or other dissociation factors such
as the ones described in b. b | Release by protein–protein interactions: p75 neurotrophin
receptor (p75NTR) and ezrin, radixin and moesin (ERM) proteins interact with RHOGDIs
and facilitate the release of RHOA, which can then be activated by specific RHOGEFs. The
interaction of p75NTR with RHOGDIs is enhanced by myelin derived proteins such as
myelin-associated glycoprotein (MAG) and neurite outgrowth inhibitor (NOGO). ERM
proteins also need to be activated to interact with RHOGDI. c | Release by phosphorylation.
Phosphorylation of RHOGDI Ser, Thr and Tyr residues promote the release of RHO
GTPases. Depending on the residues phosphorylated, this release can be specific for a single
RHO GTPase, or affect multiple RHO GTPases simultaneously (Table 1). For example p21-
activated kinase (PAK)- or FER-mediated phosphorylation promote the specific release of
RAC1, but not RHOA or CDC42. Some kinases act in concert to target the RAC1–RHODI
complex to the membrane and regulate the local release of RAC1 at specific site on the
membrane, where it is subsequently activated by RHOGEFs. Diacylglycerol kinase-ζ
(DGKζ) forms a complex with PAK, RAC1 and RHOGDI. In response to platelet derived
growth factor (PDGF), DGKζ stimulates the production of phosphatidic acid (PA), which
induces PAK activity. Active PAK then phosphorylates RHOGDI and releases RAC1 for
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activation. Positively charged phospholipids are indicated in blue, negatively charged
phopholipids in red. DAG, diacylglycerol; PDGFR, PDGF receptor.
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